Development of immunopathogenesis strategies to treat Behçet's disease

Pathology Research International

Volumn 2012, Issue , 2012, Pages

  Köse, Osman ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866236509     PISSN: None     EISSN: 2042003X     Source Type: Journal    
DOI: 10.1155/2012/261989     Document Type: Review

References (54)

1. Hirohata S., Kikuchi H., Behçet's disease. Arthritis Research and Therapy 2003 5 3 139 146 2-s2.0-0038300754
2. Köse O., Diagnosis and differential diagnosis in Behçet's disease. Turkderm Deri Hastaliklari ve Frengi Arsivi 2009 43 supplement 2 87 91 2-s2.0-79551492142
3. Krause I., ikrause@post.tau.ac.il Weinberger A., Behçet's disease. Current Opinion in Rheumatology 2008 20 1 82 87 10.1097/BOR.0b013e3282f154d1 (Pubitemid 351339436)
4. Kaneko F., f.kaneko@mt.strins.or.jp Togashi A., arihabellgasuki@yahoo.co. jp Saito S., sweetydream2009@yahoo.co.jp Sakuma H., h.sakuma@mt.strins.or.jp Oyama N., norider@wine.plala.or.jp Nakamura K., nakamu@saitama-med.ac.jp Yokota K., yokochan@md.okayama-u.ac.jp Oguma K., kuma@md.okayama-u.ac.jp Behçet's disease. Clinical and Developmental Immunology 2011 2011 681956 10.1155/2011/681956
5. Mendoza-Pinto C., García-Carrasco M., Jiménez- Hernández M., Jiménez Hernández C., Riebeling-Navarro C., Nava Zavala A., Vera Recabarren M., Espinosa G., Jara Quezada J., Cervera R., Etiopathogenesis of Behçet's disease. Autoimmunity Reviews 2010 9 4 241 245 2-s2.0-73849103894 10.1016/j.autrev.2009.10.005
6. Kapsimali V. D., meletiskanakis@yahoo.gr Kanakis M. A., Vaiopoulos G. A., Kaklamanis P. G., Etiopathogenesis of Behçet's disease with emphasison the role of immunological aberrations. Clinical Rheumatology 2010 29 11 1211 1216 10.1007/s10067-010-1491-6
7. Deniz E., edizdeniz@gmail.com Guc U., Buyukbabani N., Gul A., HSP 60 expression in recurrent oral ulcerations of Behçet's disease. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2010 110 2 196 200 10.1016/j.tripleo.2010.03.020
8. Pay S., salihp@yahoo.com Şimşek İ., Erdem H., Dinç A., Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells. Rheumatology International 2007 27 5 417 424 10.1007/s00296-006-0281-6 (Pubitemid 46294993)
9. Köse O., Stewart J., Waseem A., Lalli A., Fortune F., Expression of cytokeratins, adhesion and activation molecules in oral ulcers of Behçet's disease. Clinical and Experimental Dermatology 2008 33 1 62 69 2-s2.0-37349038271 10.1111/j.1365-2230.2007.02558.x (Pubitemid 350308528)
10. Direskeneli H., Fujita H., Akdis C. A., akdisac@siaf.uzh.ch Regulation of TH17 and regulatory T cells in patients with Behçet disease. Journal of Allergy and Clinical Immunology 2011 128 3 665 666 10.1016/j.jaci.2011.07.008
11. Kim J., Park J. A., Lee E. Y., Lee Y. J., Song Y. W., Lee E. B., leb7616@snu.ac.kr Imbalance of Th17 to Th1 cells in Behçet's disease. Clinical and Experimental Rheumatology 2010 28 4, supplement 60 S16 S19
12. Hamzaoui K., kamel.hamzaoui@gmail.com Thl7 cells In Behçet's disease: a new immunoregulatory axis. Clinical and Experimental Rheumatology 2011 29 4, supplement 67 S71 S76
13. Hamzaoui K., kamel.hamzaoui@gmail.com Borhani Haghighi A., Ghorbel I. B., Houman H., RORC and Foxp3 axis in cerebrospinal fluid of patients with Neuro-Behçet's Disease. Journal of Neuroimmunology 2011 233 1-2 249 253 10.1016/j.jneuroim.2011.01.012
14. Geri G., Terrier B., Rosenzwajg M., Wechsler B., Touzot M., Seilhean D., Tran T. -A., Bodaghi B., Musset L., Soumelis V., Klatzmann D., Cacoub P., Saadoun D., david.saadoun@psl.aphp.fr Critical role of IL-21 in modulating T H17 and regulatory T cells in Behçet disease. Journal of Allergy and Clinical Immunology 2011 128 3 655 664 10.1016/j.jaci.2011.05.029
15. Jiang Z., Yang P., Hou S., IL-23R gene confers susceptibility to Behçet's disease in a Chinese Han population. Annals of the Rheumatic Diseases 2010 69 7 1325 1328
16. Hamzaoui K., Ayed K., Hamza M., Hamzaoui A., VEGF and mRNA VEGF expression in CSF from Behçet's disease with neurological involvement. Journal of Neuroimmunology 2009 213 1-2 148 153 2-s2.0-68049137625 10.1016/j.jneuroim.2009.05.005
17. Hamzaoui K., kamel.hamzaoui@gmail.com Dhifallah I. B., Karray E., Sassi F. H., Hamzaoui A., Vitamin D modulates peripheral immunity in patients with Behçet's disease. Clinical and Experimental Rheumatology 2010 28 4, supplement 60 S50 S57
18. Alexoudi I., Kapsimali V., Vaiopoulos A., Kanakis M., Vaiopoulos G., Evaluation of current therapeutic strategies in Behçet's disease. Clinical Rheumatology 2011 30 2 157 163 2-s2.0-77956462223 10.1007/s10067-010- 1566-4
19. Pipitone N., Olivieri I., Cantini F., Triolo G., Salvarani C., New approaches in the treatment of Adamantiades-Behçet's disease. Current Opinion in Rheumatology 2006 18 1 3 9 2-s2.0-33645454451 (Pubitemid 43740399)
20. Houman M. H., Hamzaoui K., Promising new therapies for Behçet's disease. European Journal of Internal Medicine 2006 17 3 163 169 2-s2.0-33646000598 10.1016/j.ejim.2005.11.011
21. Arida A., Fragiadaki K., Giavri E., Sfikakis P., psfikakis@med.uoa.gr Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Seminars in Arthritis and Rheumatism 2011 41 1 61 70 10.1016/j.semarthrit.2010.09.002
22. Keino H., Watanabe T., Taki W., Okada A. A., Effect of infliximab on gene expression profiling in Behçet's disease. Investigative Ophthalmology & Visual Science 2011 52 10 7681 7686
23. Accardo-Palumbo A., g.triolo@unipa.it Giardina A. R., a.ritagiardina@libero.it Ciccia F., francescociccia@tiscali.it Ferrante A., angeloferrante@msn.com Principato A., g.triolo@unipa.it Impastato R., g.triolo@unipa.it Giardina E., g.triolo@unipa.it Triolo G., g.triolo@unipa.it Phenotype and functional changes of V γ 9/V δ 2 T lymphocytes in Behçet's disease and the effect of infliximab on V γ 9/V δ 2 T cell expansion, activation and cytotoxicity. Arthritis Research and Therapy 2010 12 3, article R109 10.1186/ar3043
24. Benitah N. R., Sobrin L., Papaliodis G. N., GeorgePapaliodis@meei. harvard.edu The use of biologic agents in the treatment of ocular manifestations of Behçet's disease. Seminars in Ophthalmology 2011 26 4-5 295 303 10.3109/08820538.2011.588665
25. Accorinti M., Pirraglia M. P., Paroli M. P., Priori R., Conti F., Pivetti-Pezzi P., Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Japanese Journal of Ophthalmology 2007 51 3 191 196 2-s2.0-34250004378 10.1007/s10384-006-0425-y (Pubitemid 46889493)
26. Aikawa N. E., Gonçalves C., Silva C. A.A., Gonçalves C., Bonfá E., De Carvalho J. F., jotafc@gmail.com Late response to anti-TNF- α therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatology International 2011 31 8 1097 1099 10.1007/s00296-009-1276-x
27. Markomichelakis N., Delicha E., Masselos S., Fragiadaki K., Kaklamanis P., Sfikakis P. P., A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. Rheumatology 2011 50 3 593 597 2-s2.0-79952016227 10.1093/rheumatology/keq366 keq366
28. Borhani Haghighi A., Safari A., Nazarinia M. A., Habibagahi Z., Shenavandeh S., Infliximab for patients with neuro-Behçet's disease: case series and literature review. Clinical Rheumatology 2011 30 7 1007 1012 2-s2.0-79952800944 10.1007/s10067-011-1726-1
29. Iwata S., Saito K., Yamaoka K., Tsujimura S., Nawata M., Suzuki K., Tanaka Y., tanaka@med.uoeh-u.ac.jp Effects of anti-TNF- α antibody infliximab in refractory entero-Behçet's disease. Rheumatology 2009 48 8 1012 1013 10.1093/rheumatology/kep126
30. Almoznino G., Ben-Chetrit E., eldad@hadassah.org.il Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature. Clinical and Experimental Rheumatology 2007 25 4, supplement 45 S 99
31. Iwata S., Saito K., Yamaoka K., Tsujimura S., Nawata M., Hanami K., Tanaka Y., tanaka@med.uoeh-u.ac.jp Efficacy of combination therapy of anti-TNF- α antibody infliximab and methotrexate in refractory entero- Behçet's disease. Modern Rheumatology 2011 21 2 184 191 10.1007/s10165-010-0370-y
32. Cantarini L., Tinazzi I., Caramaschi P., Bellisai F., Brogna A., Galeazzi M., Safety and efficacy of etanercept in children with juvenile-onset Behçet's disease. International Journal of Immunopathology and Pharmacology 2009 22 2 551 555 2-s2.0-67650433877
33. Curigliano V., Giovinale M., Fonnesu C., Cerquaglia C., Verrecchia E., Turco S., Manganelli C., Manna R., Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clinical Rheumatology 2008 27 7 933 936 2-s2.0-45049086684 10.1007/s10067-008-0857-5
34. Zhang M. F., Zhao C., Wen X., Du H., Zhao Y., The short-term efficacy and safety treatment study of recurrent uveitis in Behçet disease with etanercept. Chinese Journal of Ophthalmology 2010 46 2 145 150 2-s2.0-77956521636 10.3760/cma.j.issn.04124081.2010.02.011
35. Bawazeer A., Raffa L. H., Nizamuddin, Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocular Immunology and Inflammation 2010 18 3 226 232 2-s2.0-77952800736 10.3109/09273948.2010.483314
36. De Cassan C., chiaradecassan@yahoo.it De Vroey B., Dussault C., Hachulla E., Buche S., Colombel J. F., Successful treatment with adalimumab in a familial case of gastrointestinal Behçet 's disease. Journal of Crohn's and Colitis 2011 5 4 364 368 10.1016/j.crohns.2011.03.006
37. Olivieri I., ignazioolivieri@tiscalinet.it Leccese P., D'Angelo S., Padula A., Nigro A., Palazzi C., Coniglio G., Latanza L., Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clinical and Experimental Rheumatology 2011 29 4, supplement 67 S54 S57
38. Davatchi F., Shams H., Rezaipoor M., Sadeghi-Abdollahi B., Shahram F., Nadji A., Chams-Davatchi C., Akhlaghi M., Faezi T., Naderi N., Rituximab in intractable ocular lesions of Behçet's disease; randomized single-blind control study (pilot study). International Journal of Rheumatic Diseases 2010 13 3 246 252 2-s2.0-77955356607 10.1111/j.1756-185X.2010.01546.x
39. Sadreddini S., Noshad H., Molaeefard M., Noshad R., Treatment of retinal vasculitis in Behçt's disease with rituximab. Modern Rheumatology 2008 18 3 306 308 2-s2.0-46549090127 10.1007/s10165-008-0057-9
40. Lockwood C. M., Hale G., Waldman H., Jayne D. R. W., Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antivbody CAMPATH 1-H. Rheumatology 2003 42 12 1539 1544 2-s2.0-0345099473 10.1093/rheumatology/keg424 (Pubitemid 37508929)
41. Borhani Haghighi A., Safari A., Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease. Medical Hypotheses 2008 71 1 156 157 2-s2.0-44149120983 10.1016/j.mehy.2008.01.011
42. Hirano T., Ohguro N., Hohki S., Hagihara K., Shima Y., Narazaki M., Ogata A., Yoshizaki K., Kumanogoh A., Kishimoto T., Tanaka T., ttanak@imed3.med. osaka-u.ac.jp A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern Rheumatology. In press 10.1007/s10165-011-0497-5
43. Geiler J., McDermott M. F., m.mcdermott@leeds.ac.uk Gevokizumab, an anti-IL-1 β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Current Opinion in Molecular Therapeutics 2010 12 6 755 769
44. Dubois E. A., Rissmann R., Cohen A. F., Rilonacept and canakinumab. British Journal of Clinical Pharmacology 2011 71 5 639 641 10.1111/j.1365-2125. 2011.03958.x
45. Dhimolea E., Canakinumab. MAbs 2010 2 1 3 13 2-s2.0-77953665294 10.4161/mabs.2.1.10328
46. Matsuda T., Ohno S., Hirohata S., Miyanaga Y., Ujihara H., Inaba G., Nakamura S., Tanaka S. I., Kogure M., Mizushima Y., Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs in R and D 2003 4 1 19 28 2-s2.0-0041355284 10.2165/00126839-200304010-00002 (Pubitemid 37062641)
47. Bang D., Choi B., Kwon H. J., Lee E. S., Lee S., Sohn S., Rebamipide affects the efficiency of colchicine for the herpes simplex virus-induced inflammation in a Behçet's disease mouse model. European Journal of Pharmacology 2008 598 13 112 117 2-s2.0-54049154201 10.1016/j.ejphar.2008.09.005
48. Matsumura K., Nakase H., Chiba T., Efficacy of oral tacrolimus on intestinal Behçet's disease. Inflammatory Bowel Diseases 2010 16 2 188 189 2-s2.0-73949147972 10.1002/ibd.20970
49. Yalçinda F. N., yalcinda@medicine.ankara.edu.tr Batiolu F., Özdemir Ö., Penetration of topically applied tacrolimus into the aqueous humor in Behçet's disease. Annals of Ophthalmology 2007 39 1 15 17 10.1007/BF02697321 (Pubitemid 350027399)
50. Köse O., Dinç A., Şimşek I., Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet's disease. Dermatology 2009 218 2 140 145 2-s2.0-59049099968 10.1159/000182257
51. Chams-Davatchi C., Barikbin B., Shahram F., Nadji A., Moghaddassi M., Yousefi M., Davatchi F., fddh@davatchi.net Pimecrolimus versus placebo in genital aphthous ulcers of Behçet's disease: a randomized double-blind controlled trial. International Journal of Rheumatic Diseases 2010 13 3 253 258 10.1111/j.1756-185X.2010.01531.x
52. Kappen J. H., Mensink P. B. F., Lesterhuis W., Lachman S., Van Daele P. L. A., Van Hagen P. M., Van Laar J. A. M., Mycophenolate sodium: effective treatment for therapy-refractory intestinal Behçet's disease, evaluated with enteroscopy. American Journal of Gastroenterology 2008 103 12 3213 3214 2-s2.0-58149399365 10.1111/j.1572-0241.2008.0216113.x
53. Köse O., okose@gata.edu.tr Şimşek I., Pay S., Mycophenolate sodium in the treatment of mucocutaneous Behçet's diseases. International Journal of Dermatology 2011 50 7 895 896 10.1111/j.1365-4632. 2010.04505.x
54. Shugaiv E., Tüzün E., Mutlu M., Kiyat-Atamer A., Kurtuncu M., Akman-Demir G., akmandemir@yahoo.com Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. Clinical and Experimental Rheumatology 2011 29 4, supplement 67 S64 S67